Introduction
Gliomas are the most common primary tumors of the central nervous system (CNS) and glioblastoma (GBM) (grade IV according to the World Health Organization grading system) is the most aggressive glial tumor with an average overall survival of 12-18 months (Stupp et al., 2005) . Standard treatment consists of surgical resection followed by concurrent radiotherapy with the methylating agent temozolomide and subsequent adjuvant therapy with temozolomide.
Unfortunately, despite the aggressive multimodality treatment GBM uniformly recurs and efficacy of the actual salvage therapies remains modest.
Invasion of the surrounding brain parenchyma, angiogenesis and abnormal vascular permeability are all hallmarks of glioma progression. Indeed, one of the most frequently used salvage treatments is the anti-Vascular Endothelial Growth Factor (VEGF)-A monoclonal antibody (mAb) bevacizumab. However, in the recurrent setting of GBM bevacizumab failed to improve overall survival and no agents have been demonstrated to significantly affect survival after tumor progression on bevacizumab (reviewed in Diaz et al., 2017; Hundsberger et al., 2017; Tipping et al., 2017) .
Intrinsic or acquired resistance mechanisms towards anti-VEGF-A therapies include increased expression/activation of VEGF-A tyrosine kinase transmembrane receptors (in tumor and tumor microenvironment cells) and/or up-regulation of different angiogenic factors including the Placental Growth Factor (PlGF) (Hundsberger et al., 2017) . While VEGF-A binds to both VEGFR-1 (Flt-1) and VEGFR-2 (KDR, Flk-1) receptors, PlGF interacts exclusively with VEGFR-1. VEGF-A is known to favor angiogenesis by activating VEGFRs expressed on tumor endothelium, but it also directly interacts with the receptors expressed on cancer cells contributing to disease progression. In regard to PlGF, this growth factor seems to have an important disease-associated role because its expression is up-regulated in a number of This article has not been copyedited and formatted. The final version may differ from this version. JPET Fast Forward. Published on October 12, 2017 as DOI: 10.1124 at ASPET Journals on jpet.aspetjournals.org Downloaded from JPET #244434 6 pathological conditions including cancer (Ferrara et al., 2003; Fischer et al., 2008; Kim et al. 2012; Dewerchin and Carmeliet P, 2014) . PlGF is secreted by tumor, endothelial, and other cells of the tumor stroma including inflammatory cells.
It is generally agreed that VEGFR-2 is the major receptor mediating the mitogenic, angiogenic and permeability-enhancing effects of VEGF-A and therefore it has received much attention for therapeutic inhibition of angiogenesis. However, therapies that target VEGF-A or VEGFR-2 give rise to systemic toxicity, due to the inhibition of physiological angiogenesis, resulting in bleeding, hypertension, delayed wound healing, etc. (Higa and Abraham, 2009 ). On the other hand, VEGFR-1-mediated signaling has a prevalent role in pathological angiogenesis (Shibuya, 2006; Luttun et al., 2002; Dewerchin and Carmeliet, 2014) . VEGFR-1 is expressed in endothelial cells during vessel formation, in macrophages, myoepithelial cells, and a in variety of human cancers where it stimulates cell migration and survival, inhibits apoptosis, induces chemoresistance and predicts poor prognosis and recurrence (Wu et al., 2006; Roskoski, 2008; Schwartz et al., 2010; Takahashi, 2011) . Moreover, VEGFR-1 is involved in the mobilization of bone marrow-derived cells that generate tumor-associated macrophages which foster tumor growth and angiogenesis Qian et al., 2015; Graziani et al., 2016) . Besides the transmembrane receptor, a soluble form of VEGFR-1 is released in the extracellular matrix (ECM) where it may sequester VEGF-A avoiding its interaction with the membrane receptors (Cao et al., 2009) . In high grade gliomas the co-expression of VEGF-A and its receptors in a consistent percentage of patient-derived tumor cells suggested the presence of an autocrine loop that may favor tumor progression (Steiner et al., 2004) . Moreover, we have recently demonstrated that stimulation by PlGF of VEGFR-1 can itself transmit signals that promote GBM cell invasiveness (Atzori et al., 2017) .
In this context, we hypothesized that molecules selectively targeting VEGFR-1 may inhibit tumor vascularization and invasiveness while producing less toxic effects than agents directed This article has not been copyedited and formatted. The final version may differ from this version. JPET Fast Forward. Published on October 12, 2017 as DOI: 10.1124 at ASPET Journals on November 19, 2017 jpet.aspetjournals.org Downloaded from JPET #244434 7 against VEGF-A or VEGFR-2. Therefore, we generated an anti-VEGFR-1 mAb (D16F7) that while not affecting binding of VEGF-A and PlGF to the receptor, reduces its homodimerization and activation by both ligands. This property allows the mAb to preserve the soluble VEGFR-1 ability of acting as decoy receptor. The mAb exerted inhibitory effects on migration and/or ECM invasion by tumor cells (melanoma, GBM) and tumor microenvironment cells (endothelial and myelomonocytic cells) in response to VEGFR-1 ligands in vitro, and on pathological angiogenesis in vivo Atzori et al., 2017) .
Herein we analyze the in vivo therapeutic potential of D16F7 mAb against glioma using rat C6 cells transduced to overexpress the human VEGFR-1. The results of this study indicate that in nude mice D16F7 is well tolerated, inhibits glioma growth and tumor-associated vessel formation, and increases median survival time with a high percentage of long-term survivors.
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Materials and methods

Cell lines, culture conditions and transfection
The rat glioma cell line C6 was obtained from American Type Culture Collection (ATCC, Manassas, VA). Cells were maintained in DMEM (Sigma-Aldrich, St. Louis, MO) supplemented with 10% fetal bovine serum (FBS, Sigma-Aldrich), 2 mM L-glutamine, 100 units/ml penicillin, and 100 μg/ml streptomycin sulfate, at 37°C in a 5% CO2 humidified atmosphere.
Cell clones were obtained by limiting dilution from C6 cells and one clone was transfected with pBLAS49.2 or pBLAS49.2/VEGFR-1 plasmids. The pBLAS49.2/VEGFR-1 construct was obtained by cloning of VEGFR-1 cDNA from pcDNA3/VEGFR-1 plasmid (a generous gift of Dr. K. Ballmer-Hofer, PSI, Zurich) into pBLAS49.2 vector (InvivoGen, San Diego, CA).
Transfection was performed using lipofectamine 2000 (Invitrogen, Camarillo, CA), as described by the manufacturer, and transfected cells were selected in blasticidine (Invitrogen)-containing culture medium. Antibiotic resistant clones were isolated by ring cloning and transfected clones maintained in the presence of 5 µg/ml blasticidine.
Analysis of VEGFR-1 transcript
Detection of VEGFR-1 transcript in transfected clones was evaluated by RT-PCR analysis and cDNA preparation, followed by PCR amplification to evaluate VEGFR-1 expression, were performed as previously described (Tentori et al., 2005) , utilizing an annealing temperature of 58°C and the following primers: human VEGFR-1, forward primer 5'-CTCCTGAGTACTCTACTCCT-3', reverse primer 5'-GAGTACAGGACCACCGAGTT-3' (640 bp fragment); glyceraldehyde-3-phosphate dehydrogenase (GAPDH), forward primer 5'-TCCCATCACCATCTTCCA-3', reverse primer 5'-CATCACGCCACAGTTTCC-3'. The 
Western blot analysis
Proteins were run in 10% SDS-polyacrylamide gels and transferred to supported nitrocellulose membranes by standard techniques. Immunodetection was performed using the following antibodies: mouse monoclonal anti-VEGFR-1 (clone D2, 1:500; Santa Cruz Biotechnology, Santa Cruz, CA); rabbit polyclonal anti-phosphorylated VEGFR-1 at tyrosine 1213 (1:500; R&D Systems, Abingdon, UK); rabbit polyclonal anti-Erk1&2 (1:1000; GeneTex, Irvine, CA); rabbit polyclonal anti-phospho-Erk1&2 (Thr/Tyr185/187, 1:1000; Invitrogen); or rabbit polyclonal anti-β-actin (1:10,000; Sigma-Aldrich) primary antibodies. The anti-VEGFR-1 antibodies recognize only the human protein, while the anti-Erk1/2 antibodies have wide species reactivity, including the human and rat proteins. Anti-mouse or anti-rabbit Ig/Horseradish peroxidase secondary antibodies and ECL Western blotting detection reagents from GE Healthcare (Milan, Italy), were used to identify the proteins of interest.
For the analysis of VEGFR-1 and Erk1/2 phosphorylation, cells (1x10 6 /well) were seeded in 6-well plates, allowed to growth overnight in complete medium, starved for 2 h in serum-free medium [DMEM containing 0.1% fatty acid-free bovine serum albumin (BSA; Roche, Mannheim, Germany) and 1 μg/ml heparin] and pre-incubated for 30 min at room temperature with the indicated concentrations of D16F7 mAb before stimulation for 10 min at 37°C with VEGF-A or PlGF (100 ng/ml). Cells were then washed twice with PBS containing protease and phosphatase inhibitors (ThermoFisher Scientific, Waltham, MA), directly lysed by SDSelectrophoresis sample buffer and analyzed by Western blotting.
Chemotaxis assay and spheroid invasion assay
This article has not been copyedited and formatted. The final version may differ from this version. In vitro migration assay was performed using Boyden chambers equipped with 8 µm pore diameter polycarbonate filters (Nuclepore, Whatman Incorporated, Clifton, NJ) coated with 5 µg/ml gelatin (Sigma-Aldrich), as previously described (Lacal et al., 2008) . Untreated cells or cells treated with the indicated amounts of D16F7 mAb or of an isotype matched control (IgG1; R&D Systems) were incubated in a rotating wheel for 30 min at room temperature. Cells (2x10 5 /chamber) were then loaded in the upper compartment of Boyden chambers and migration assay, toward serum-free medium (containing 0.1% BSA and 1 µg/ml heparin) or stimuli (50 ng/ml VEGF-A or PlGF) present in the lower compartment, was performed in the absence or in the presence of D16F7 mAb for the time specified in figure legends. Migrated cells, attached to the lower side of the filters, were stained with crystal violet and counted in triplicate samples for a total of 12 high power (200x magnification) microscopic fields.
For spheroid invasion assay, tumor cells (25,000-30,000 cells/ml) were suspended in DMEM-1640, containing 10% FBS, supplemented with methyl cellulose (0.24% final concentration; Sigma-Aldrich), seeded in 96-well round bottom cell culture plates (100 μl/well; Corning® Costar® Ultra-Low attachment multi-well, Sigma-Aldrich) and centrifuged at 3000 rpm for 90 min (Eskilsson et al., 2016) . Plates were then incubated for 24 h under standard culture conditions (5% CO2, at 37°C) to allow spheroid formation. Spheroids were collected, embedded individually in 100 μl of 1 mg/ml collagen I solution (rat tail, Trevigen®, Gaithersburg, MD) in 0.1% BSA/DMEM, with or without PlGF or VEGF-A (50 ng/ml) and/or 10 μg/ml D16F7 mAb, and plated in each well of a 96-well flat bottom plate, previously coated with 50 μl of collagen I. Five to eight replicates were set up for each experimental group. Collagen I dilution and neutralization were performed according to the manufacturer's instructions. After collagen I solidification at 37°C, 100 μl of invasion medium, with or without PlGF or VEGF-A (50 ng/ml), were added and plates incubated overnight at 37°C for up to 72 h. Spheroids were visualized and photographed using a Nikon Eclipse TS100 microscope in conjunction with a Animals were euthanized, for ethical reasons, when tumor volume reached ~2000 mm 3 .
Body weight (BW) was measured on alternate days and toxicity was evaluated on the basis of net BW reduction. The percentage of net BW variation between the first day of treatment and the day of interest, was evaluated according to the following equation:
% net BW variation = [(net BW at observation day -net BW at first day of treatment)/net BW at first day of treatment] × 100.
The intracranial transplantation procedure was performed as previously described (Tentori et al., 2003) . Briefly, cells (10JPET #244434 13 ketamine/xylazine solution at the dose of 100 mg/kg and 12.5 mg/kg, respectively (Ketavet 100 mg/ml, MSD Animal Health, Milan, Italy; Rompum, 20 mg/ml, Bayer, Milan, Italy). Treatment with D16F7 (10 mg/kg and 20 mg/kg) was started the day after tumor challenge. Body weight was measured thrice weekly; survivals were recorded for 60 days and median survival times were determined. Animals were euthanized, for ethical reasons, when a loss >20% of body weight or signs of neurological deficit were present.
Histological examination of the brains was performed using additional animals that were not considered for the calculation of survival times. At sacrifice, brains were excised, fixed in 10% buffered formalin solution (v/v), paraffin embedded and cut into 5 µm-thick slices for staining.
A set of slides was stained with hematoxylin-eosin for morphological study, mitotic and apoptotic cell counts. Additional slides were stained with anti-mouse PECAM/CD31 goat polyclonal antibody Santa Cruz Biotechnology) , to label blood vessels. Reactions were revealed with 3,30-diaminobenzidine. 
Statistical analyses
Statistical analysis of the differences between pairs of groups was performed by Student's t test.
For multiple comparisons ANOVA followed by Bonferroni's post-test was used. Survival curves were generated by Kaplan-Meier product-limit estimate and statistical differences 
Results
The anti-VEGFR-1 D16F7 mAb inhibits migration, ECM invasion and receptor activation in response to VEGF-A and PlGF in C6 cells transfected with the human
VEGFR-1
We recently demonstrated that the anti-VEGFR-1 D16F7 mAb inhibits human melanoma and GBM chemotaxis in response to PlGF Atzori et al., 2017) . For this study, aimed at evaluating the in vivo efficacy of D16F7 against glioma, the rat C6 glioma cell line was chosen since it forms highly angiogenic gliomas when injected in vivo, similarly to the same tumors of human origin. Moreover, C6 glioma has been widely used as a reliable model of GBM, presenting high similarity with human glioma also in the gene expression pattern during tumor progression (Grobben B et al., 2002) . Since the expression of VEGFR-1 protein in C6 cells is undetectable (Plate et al., 1993; Leopol'd et al., 2012) Figure 1C ). On the other hand a species and isotype matched control (IgG1) did not affect
PlGF-induced tumor cell migration ( Figure 1D ), in accordance with previous studies Atzori et al., 2017) . Treatment with D16F7 of C6-MF1 cells reduced not only chemotaxis (Figure 2A and B) but also ECM invasion ( Figure 2C and D) in response to both PlGF and VEGF-A.
We then investigated whether receptor stimulation in transfected cells by the VEGFR-1 selective ligand PlGF might cause receptor phosphorylation at Tyr 1213, which is regarded as one of the major auto-phosphorylation sites responsible for activation of intracellular signaling pathways (Igarashi et al., 1998 , Yu et al., 2001 , and whether D16F7 could inhibit this effect.
Exposure of C6-MF1 cells to PlGF for 10 min markedly increased VEGFR-1 protein phosphorylation and D16F7 reduced receptor tyrosine kinase activity ( Figure 3A) . Similarly VEGF-A induced VEGFR-1 phosphorylation at Tyr 1213, and also in this case D16F7
substantially reduced VEGFR-1 phosphorylation triggered by this angiogenic factor ( Figure   3B ). Comparable results were obtained in another VEGFR-1 transfected clone (i.e. C6-MF3;
Supplemental Figure 1 ).
Since VEGFR-1 activation by VEGF-A or PlGF stimulates Erk1/2 of the MAPK signaling pathway, promoting tumor cell invasion and migration (Koch et al., 2011; Atzori et al., 2017) , we investigated whether VEGF-A-or PlGF-induced receptor auto-phosphorylation at Tyr 1213 in C6-MF1 cells was followed by Erk1/2 phosphorylation, and whether D16F7 could prevent Erk1/2 activation. Notably, D16F7 markedly inhibited Erk1/2 phosphorylation stimulated by both ligands ( Figure 3A and E). Quantitative results are reported as percentage inhibition of VEGFR-1 and Erk1/2 phosphorylation by D16F7 ( Figure 3C ). 
D16F7 inhibits GBM growth and angiogenesis in vivo
We recently demonstrated that 10 or 20 mg/kg D16F7 i.p. treatment is well tolerated and exerts antitumor activity in a melanoma syngeneic mouse model . The in vivo antitumor activity of D16F7 against C6-MF1 was tested in immunodeficient mice, since spontaneous tumor regression has been described when C6 cells were injected in syngeneic rats (Vince et al., 2004) . D16F7 mAb recognizes both human and murine VEGFR-1, likely due to a difference of two amino acids only between the peptide used as immunogen and the corresponding region of murine VEGFR-1. Indeed, ELISA using the human and murine VEGFR-1 extra-cellular domain showed that D16F7 specifically binds not only the human type 1 receptor, as previously reported , but also the murine protein with similar affinity (Supplemental Figure 2) . Thus, D16F7 allows the analysis of mAb effect on tumor graft and host tumor microenvironment as well.
The effect of D16F7 on glioma growth was initially evaluated by injecting C6-MF1 cells i.m.
in athymic nude mice and, when tumors were palpable, treating them with 20 mg/kg D16F7 i.p.
on alternate days for 2 weeks. Treatment with D16F7 did not cause toxic effects. In fact, compared with control animals treated with mAb solvent, no significant changes in body weight were observed in mice treated with D16F7 ( Figure 4A ). Substantial reduction in tumor volume was observed in D16F7 treated animals ( Figure 4B ). In fact, D16F7 treatment resulted in 50% inhibition of tumor growth on day 12 post tumor challenge, significantly increased tumor growth doubling time (CTR, 5.1±0.9 vs D16F7, 10.8±0.5; p<0.0001) and imposed a tumor growth delay index of 2.11 ±0.08.
We next injected C6-MF1 cells i.c., and, on day 1 post-tumor challenge, mice were treated with 10 or 20 mg/kg D16F7 i.p. on alternate days for 4 weeks. Survival analysis revealed that D16F7 treatment increased life-span by 40% and 65% at 10 and 20 mg/kg doses, respectively ( Figure   5A ). In fact, the median survival time of control animals was 20 days (range 18-28) while Neoplastic cells showed a regressive aspect characterized by shrunken nuclei, condensed chromatin, pycnosis and apoptotic pictures ( Figure 5B ). Indeed, compared with control samples, sections from D16F7-treated animals revealed reduced mitotic activity and increased apoptotic cell number ( Figure 5B ).
Discussion
In the present study we demonstrate for the first time that a novel anti-VEGFR-1 mAb (D16F7), which in vitro diminishes receptor activation by its ligands VEGF-A and PlGF, as single agent decreases glioma growth and angiogenesis in vivo in an orthotopic xenograft model.
VEGFR-1 is expressed in endothelial cells of tumor-associated vessels but it is absent from endothelial cells in the normal brain (Plate et al., 1993) , which restricts the action of VEGF and PlGF to tumor endothelium. Moreover, studies performed in a cohort of high grade glioma patients have shown that VEGFR-1 is also expressed in tumor cells (Atzori et al., 2017) and at significantly higher levels compared with lower grade gliomas (Baumgarten et al., 2016) .
VEGFR-1 can transmit signals that promote GBM cell invasion and, since both VEGFR-1 and its ligands are frequently expressed by GBM cells, D16F7 is expected to interrupt an autocrine loop that favors tumor aggressiveness. Indeed, besides VEGF-A, also the selective VEGFR-1 ligand PlGF has been found to be expressed in high grade gliomas where it stimulates angiogenesis either directly or by enhancing VEGF-driven angiogenesis (Fischer et al., 2008) . demonstrated that systemically administered D16F7 was effective also against glioma cells growing at the CNS site. The antitumor activity was associated with reduced vessel formation, induction of apoptosis and decreased proliferative potential in glioma cells. The antiangiogenic effects exerted by D16F7 in the murine model is due to the mAb ability of recognizing also the mouse VEGFR-1. Indeed, we found that D16F7 was able to bind in vitro the extra-cellular domain of the purified murine and human VEGFR-1 protein with similar affinity. Therefore, this property of D16F7 allows to observe the influence of VEGFR-1 blockade not only on glioma cells but also on the tumor microenvironment.
The growth inhibitory activity exerted by D16F7 on glioma growth translated in a dosedependent and statistically significant increase of tumor-bearing mice survival time.
Interestingly, treatment with 20 mg/kg D16F7 led to a high percentage of long-term survivors.
These data are in agreement with VEGFR-1 involvement in GBM cell viability in vivo as demonstrated by the survival benefit observed upon injection of VEGFR-1 silenced cancer cells in nude mice (Szabo et al., 2016) . The antibodies anti-VEGFR-1 generated so far have been designed to inhibit receptor activity by preventing the interaction with its ligands (Wu et al., 2006) . Conversely, D16F7 has an innovative mechanism of action since it does not affect the ligand binding to the transmembrane tyrosine kinase receptor, while it inhibits receptor autophosphorylation and signal transduction ( Figure 6 ). Consequently, D16F7 leaves intact the ability of the soluble VEGFR-1 to sequester VEGF-A and PlGF. This is particularly important considering the previously suggested role of the soluble receptor in controlling tumor progression. In fact, in GBM low soluble VEGFR-1/VEGF-A ratio has been related to higher aggressiveness compared with astrocytomas (Lamszus et al., 2003) . In addition, soluble VEGFR-1 exerts chemotactic effects on endothelial cells (Figure 6 ), indicating a role for this receptor isoform in angiogenesis (Orecchia et al., 2003; Graziani et al., 2016) . Interestingly, D16F7 was found to impair endothelial cell migration in response to soluble VEGFR-1 (Figure 6 ), counteracting its paradoxical proangiogenic effect . Moreover, since VEGF-A has a higher affinity for VEGFR-1 than VEGFR-2 (Shibuya, 2011), a molecule like D16F7 that does not compete with VEGF-A for the binding to the receptor is expected to exert antitumor/antiangiogenic effects at lower concentrations than mAbs that inhibit the interaction of the ligands with VEGFR-1 in a competitive way.
The favorable tolerability profile of D16F7 may be explained with the lack of VEGFR-1 involvement in physiological angiogenesis, and it is predictable that this mAb will improve the clinical response to therapies directed towards VEGF-A/VEGFR-2 or to chemotherapeutic and targeted agents without additive toxicity.
In conclusion, the results presented indicate that VEGFR-1 is an appropriate target for reducing glioma aggressiveness promoted by VEGF-A and PlGF, and that D16F7-derived humanized mAbs warrant further investigation for therapeutic intervention of high grade glioma.
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